Mistral Pharma files a proposal under the bankruptcy and insolvency act
> To know more...

Mistral Pharma obtains an extension to make its proposal under the bankruptcy and insolvency act
> To know more...

Enter your e-mail :

Mistral Pharma Inc. is a pharmaceutical company specializing in the development of controlled-delivery branded products. Mistral Pharma can formulate, develop and commercialize controlled-release, oral pharmaceutical product.

Mistral Pharma licensed worldwide rights to PROCISE™, an oral, controlled-release, drug delivery technology developed and patented by GlaxoSmithKline (GSK), based on a constant surface area concept. In addition, Mistral Pharma licensed from Savit Consulting Inc. the exclusive worldwide rights to SAVIT™ and CHRONOP™, two next-generation surface area controlling oral drug delivery technologies.

These drug delivery technologies have powerful competitive advantages over existing technologies: unprecedented levels of precision and flexibility in drug release profiles, ease of development and simplicity of manufacturing. SAVIT™ and CHRONOP™ allow the release of different active ingredients with variable release profiles, including pulses.